vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Currenc Group Inc. (CURR). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $10.1M, roughly 1.1× Currenc Group Inc.). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -46.5%, a 70.0% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -23.3%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
ABUS vs CURR — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $10.1M |
| Net Profit | $2.5M | $-4.7M |
| Gross Margin | — | 31.8% |
| Operating Margin | 13.9% | -43.0% |
| Net Margin | 23.5% | -46.5% |
| Revenue YoY | 522.2% | -23.3% |
| Net Profit YoY | 112.7% | -54.0% |
| EPS (diluted) | $0.01 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $10.7M | — | ||
| Q1 25 | — | $10.1M | ||
| Q3 24 | — | $11.3M | ||
| Q1 24 | — | $13.1M | ||
| Q4 23 | $2.1M | — | ||
| Q3 23 | $4.7M | $12.7M | ||
| Q2 23 | $4.7M | — | ||
| Q1 23 | $6.7M | — |
| Q2 25 | $2.5M | — | ||
| Q1 25 | — | $-4.7M | ||
| Q3 24 | — | $-5.0M | ||
| Q1 24 | — | $-3.0M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-20.1M | $-3.8M | ||
| Q2 23 | $-17.1M | — | ||
| Q1 23 | $-16.3M | — |
| Q2 25 | — | — | ||
| Q1 25 | — | 31.8% | ||
| Q3 24 | — | 27.8% | ||
| Q1 24 | — | 33.6% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | 32.5% | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q2 25 | 13.9% | — | ||
| Q1 25 | — | -43.0% | ||
| Q3 24 | — | -141.5% | ||
| Q1 24 | — | -10.8% | ||
| Q4 23 | -967.2% | — | ||
| Q3 23 | -462.8% | -18.2% | ||
| Q2 23 | -395.3% | — | ||
| Q1 23 | -260.4% | — |
| Q2 25 | 23.5% | — | ||
| Q1 25 | — | -46.5% | ||
| Q3 24 | — | -44.1% | ||
| Q1 24 | — | -23.2% | ||
| Q4 23 | — | — | ||
| Q3 23 | -431.6% | -30.1% | ||
| Q2 23 | -367.5% | — | ||
| Q1 23 | -244.3% | — |
| Q2 25 | $0.01 | — | ||
| Q1 25 | — | $-0.13 | ||
| Q3 24 | — | $-0.13 | ||
| Q1 24 | — | $-0.09 | ||
| Q4 23 | $-0.12 | — | ||
| Q3 23 | $-0.12 | $-0.11 | ||
| Q2 23 | $-0.10 | — | ||
| Q1 23 | $-0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $62.3M |
| Total DebtLower is stronger | $0 | $3.7M |
| Stockholders' EquityBook value | $83.0M | $-68.4M |
| Total Assets | $103.3M | $110.8M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $37.4M | — | ||
| Q1 25 | — | $62.3M | ||
| Q3 24 | — | $49.1M | ||
| Q1 24 | — | — | ||
| Q4 23 | $126.0M | — | ||
| Q3 23 | $17.5M | — | ||
| Q2 23 | $27.2M | — | ||
| Q1 23 | $40.6M | — |
| Q2 25 | $0 | — | ||
| Q1 25 | — | $3.7M | ||
| Q3 24 | — | $20.1M | ||
| Q1 24 | — | — | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — | ||
| Q1 23 | $0 | — |
| Q2 25 | $83.0M | — | ||
| Q1 25 | — | $-68.4M | ||
| Q3 24 | — | $-47.0M | ||
| Q1 24 | — | $-10.9M | ||
| Q4 23 | $106.0M | — | ||
| Q3 23 | $119.3M | $-10.2M | ||
| Q2 23 | $134.7M | — | ||
| Q1 23 | $143.9M | — |
| Q2 25 | $103.3M | — | ||
| Q1 25 | — | $110.8M | ||
| Q3 24 | — | $115.0M | ||
| Q1 24 | — | $54.5M | ||
| Q4 23 | $144.4M | — | ||
| Q3 23 | $158.6M | $82.0M | ||
| Q2 23 | $176.8M | — | ||
| Q1 23 | $191.2M | — |
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.00× | — | ||
| Q3 23 | 0.00× | — | ||
| Q2 23 | 0.00× | — | ||
| Q1 23 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-1.5M |
| Free Cash FlowOCF − Capex | — | $-1.7M |
| FCF MarginFCF / Revenue | — | -16.5% |
| Capex IntensityCapex / Revenue | 0.0% | 1.7% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-15.7M | — | ||
| Q1 25 | — | $-1.5M | ||
| Q3 24 | — | $-11.3M | ||
| Q1 24 | — | $-221.0K | ||
| Q4 23 | $-17.3M | — | ||
| Q3 23 | $-21.8M | $-10.5M | ||
| Q2 23 | $-19.6M | — | ||
| Q1 23 | $-27.3M | — |
| Q2 25 | — | — | ||
| Q1 25 | — | $-1.7M | ||
| Q3 24 | — | — | ||
| Q1 24 | — | $-233.0K | ||
| Q4 23 | — | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-20.4M | — | ||
| Q1 23 | $-27.4M | — |
| Q2 25 | — | — | ||
| Q1 25 | — | -16.5% | ||
| Q3 24 | — | — | ||
| Q1 24 | — | -1.8% | ||
| Q4 23 | — | — | ||
| Q3 23 | -468.4% | — | ||
| Q2 23 | -439.0% | — | ||
| Q1 23 | -410.0% | — |
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | 1.7% | ||
| Q3 24 | — | — | ||
| Q1 24 | — | 0.1% | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.7% | — | ||
| Q2 23 | 18.5% | — | ||
| Q1 23 | 1.7% | — |
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
CURR
| Sales Of Airtime | $5.5M | 54% |
| Fiat Remittance Service | $4.4M | 44% |
